Agios Pharmaceuticals, Inc. $AGIO Shares Sold by Price T Rowe Associates Inc. MD

Key Points

• Price T Rowe Associates Inc. MD lowered its stake in Agios Pharmaceuticals by 5.0%, holding 2,301,353 shares worth approximately $67.4 million after selling 122,184 shares in the first quarter.
• Agios Pharmaceuticals reported earnings of ($1.93) per share, missing estimates, but had revenues of $12.5 million exceeding expectations, indicating a strong performance despite the loss.
• Analysts have mixed views on AGIO, with a consensus price target of $56.33, reflecting a mix of buy and hold ratings, while Scotiabank recently adjusted their target downward from $71.00 to $65.00.

Price T Rowe Associates Inc. MD trimmed its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 5.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,301,353 shares of the biopharmaceutical company's stock after selling 122,184 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 3.97% of Agios Pharmaceuticals worth $67,430,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Erste Asset Management GmbH increased its holdings in shares of Agios Pharmaceuticals by 10.9% in the 1st quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company's stock valued at $65,439,000 after acquiring an additional 220,000 shares during the period. Jefferies Financial Group Inc. bought a new position in Agios Pharmaceuticals in the fourth quarter worth about $49,290,000. Frazier Life Sciences Management L.P. raised its holdings in Agios Pharmaceuticals by 2.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company's stock worth $35,152,000 after purchasing an additional 25,600 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Agios Pharmaceuticals by 39.7% during the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock valued at $30,732,000 after buying an additional 265,637 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC boosted its holdings in shares of Agios Pharmaceuticals by 3.9% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 917,420 shares of the biopharmaceutical company's stock valued at $30,146,000 after buying an additional 34,689 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Bank of America reduced their price target on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Scotiabank reduced their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a research report on Monday, July 28th. Finally, Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, Agios Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $56.33.

Insider Buying and Selling

In related news, insider Tsveta Milanova sold 2,770 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $92,905.80. Following the completion of the sale, the insider owned 26,122 shares of the company's stock, valued at approximately $876,131.88. This trade represents a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Brian Goff sold 18,700 shares of Agios Pharmaceuticals stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $627,198.00. Following the transaction, the chief executive officer owned 105,401 shares in the company, valued at approximately $3,535,149.54. This represents a 15.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 57,448 shares of company stock worth $2,026,141 in the last ninety days. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO traded down $0.47 during mid-day trading on Monday, hitting $37.71. The stock had a trading volume of 502,787 shares, compared to its average volume of 844,455. The firm has a market cap of $2.19 billion, a PE ratio of 3.43 and a beta of 0.87. The company has a 50 day moving average of $37.21 and a two-hundred day moving average of $33.08. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). The business had revenue of $12.50 million for the quarter, compared to analysts' expectations of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. Equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.